Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
Gossamer Bio Inc (NASDAQ:GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12.  Gossamer will terminate the ongoing treat-through and open-label extension portions of the…
Benzinga
Benzinga
Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen
Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen
Molecular Partners AG's (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review.  MP0310 is a dual-targeted compound targeting both FAP and 4-1BB that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming…
Benzinga
Benzinga
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody.  Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said…
Benzinga
Benzinga
Otonomy Hearing Loss Candidate Shows Clinical Benefit On Multiple Efficacy Endpoints
Otonomy Inc (NASDAQ:OTIC) announced topline results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The trial demonstrated that a single intratympanic injection of 0.3 mg OTO-413 provided clinically meaningful treatment benefit versus placebo across multiple speech-in-noise (SIN) hearing tests and the Patient Global Impression of Change at consecutive…
Benzinga
Benzinga
From analysis to the latest developments in health, read the most diverse news in one place.
Already a member? Sign in here
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ:CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary technology to harness the immune system's power to combat cancer. The offer price represents a whopping premium of over 300% on…
Benzinga
Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
The FDA has accepted for review AstraZeneca plc (NASDAQ:AZN) - Daiichi Sankyo's (OTC:DSNKY) supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for non-small cell lung cancer (NSCLC) setting. The application covers unresectable or metastatic NSCLC whose tumors have a HER2 (ERBB2) mutation and who have received prior systemic therapy.  The application has also been…
Benzinga
Benzinga